University of California-San Francisco · BiologyThe AML Innovation Lab
Arun P. Wiita · San Francisco, California
Research Focus
Dr. Arun P. Wiita's lab at UCSF focuses on developing innovative therapies for acute myeloid leukemia (AML), a challenging blood cancer. Their research combines proteomics and immunotherapy techniques to identify and exploit unique surface proteins on cancer cells, aiming to create targeted treatments that are both effective and less toxic than existing options. The lab's recent work on radioimmunotherapy is poised to significantly improve patient outcomes in AML.
acute myeloid leukemiaimmunotherapyradioimmunotherapysurface proteinsproteomics
Research Aims
5AIM 01Identify new immunotherapy targets using structural surfaceomics technology.
AIM 02Evaluate the efficacy and safety of a novel radioimmunotherapy for AML.
AIM 03Optimize conformation-specific targeting strategies for aITGB2 in leukemia.
AIM 04Conduct preclinical evaluations to support future clinical trial designs.
AIM 05Study mechanisms of resistance to the new therapy in AML.
Skills the Lab Values
cell cultureflow cytometryanimal modelsantibody engineeringmass spectrometryneoplasm modelingtherapeutic trial designdata analysis in proteomicsCAR T-cell development
Output against the department
Publications327top 16% of dept.164th of 1,033
this lab
most publishedleast published
Citations6.2kbottom 45% of dept.572nd of 1,033
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.